Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 242

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 242
---
 necessary data or results required to obtain marketing approval and achieve
product sales. In addition, the Company’s product candidates, if approved, may not achieve commercial success. Commercial revenues,
if any, will be derived from sales of product candidates that the Company does not expect to be commercially available in the near term,
if at all. Accordingly, the Company will need to continue to rely on additional financing to achieve its business objectives. Adequate
additional financing may not be available to the Company on acceptable terms, or at all. To the extent that the Company raises additional
capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict the
Company’s ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and
restricting the ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing
or other arrangements or declaring dividends. If the Company raises additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its technologies, future
revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to the Company. If the
Company is unable to raise capital when needed or on acceptable terms, the Company could be forced to delay, reduce or eliminate its
R&D programs or future commercialization efforts.

Cash Flows

    For the Nine Months Ended September 30,  

    2024  

    2025 (Successor)  
    (Pro forma, Predecessor and Successor)  
    Difference 

    Net cash used in operating activities 
    $(12,273,817) 
    $(11,375,873) 
    $(897,944)
  
    Net cash provided by investing activities 
     500,000  
     -  
     500,000 
  
    Net cash provided by financing activities: 
     10,468,829  
     12,240,682  
     (1,771,853)
  
    Net (decrease) increase in cash, restricted cash and cash equivalents 
    $(1,304,988) 
    $864,809  
    $(2,169,797)

Net cash used in operating activities

Net cash used in operating activities for the nine months ended September
30, 2025 primarily reflected a net loss of